Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119419) titled 'Real-World Effectiveness of Adding Haibomeib on Top of Statin Therapy for Very High-Risk ASCVD' on Feb. 26.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Condition:
high-risk atherosclerotic cardiovascular disease (ASCVD)
Intervention:
statin:N/A
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-26
Target Sample Size: statin:130;Hybutimibe Tablets and statin:130;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=311608
Publi...